Report: PBM Gross Profits Rose 12% From 2017-2019

Pharmaceutical middlemen saw gross profits increase by 12% from 2017 to 2019, according to a report by the PBM Accountability Project . The report said the source of profits varied substantially and included common tactics such as spread pricing and retroactive claw back fees...


Read full story >